Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. based media - Fertility.com is the gateway to two online portals: - Offering the latest scientific information to healthcare professionals in the advancing field of fertility - Supporting women, men and couples who are looking for information about fertility and/or undergoing fertility treatment (Photo: ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. based media - QBOX IVF streamlines data transfer between lab instruments and Electronic Medical Record providers - Geri® Assess 2.0 enables automatic detection of key events in embryo and blastocyst development, improving efficiencies in assessment - Merck demonstrates commitment to further advance and ...
Darmstadt, Germany (ots/PRNewswire) - - 14 abstracts to be presented, further characterizing the complementary profiles of Mavenclad (cladribine tablets)and Rebif (interferon beta-1a) Merck, a leading science and technology company, will present data from its neurology and immunology portfolio at the 4th Congress of ...
Aachen, Germany (ots) - Grünenthal announced today that first patients have been enrolled in two trials of the company's pivotal phase III program investigating neridronate for the treatment of Complex Regional Pain Syndrome (CRPS). These two trials, KF7013-02 and KF7013-04, are investigating the efficacy and safety of neridronate in 360 patients with CRPS. ...
Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - M7824 is an investigational immunotherapy that is designed to bring together ...
Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - Data from an ongoing Phase II tepotinib study show anti-tumor clinical activity in ...
Darmstadt, Germany (ots/PRNewswire) - - Launch of #MSInsideOut campaign, aimed at providing a deeper understanding of multiple sclerosis (MS) - Donation to the MS International Federation (MSIF)* of up to EUR20,000 - Shift.ms to Executive Produce a documentary to highlight stories and unique perspectives within the ...
Cadenberge, Germany and Montreal (ots/PRNewswire) - Hartmann Family and The CSL Group ("CSL") are pleased to announce they have formed a 50/50 joint venture to build and operate a 40,000 DWT gravity self-unloading vessel to trade in Europe. The new ship will be built at Chengxi Shipyard in China and is scheduled for delivery in Germany in 2020. It will service Mibau Stema Group on a long-term charter. The joint venture ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ASCO Abstract # ERBITUX® (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase inhibitor): 9082, 9016; M6620 (ATR inhibitor): 2549, e21048; M3814 (DNA-PK): 2518 M7824 (TGF-ß ...
Darmstadt, Germany (ots/PRNewswire) - - Post-hoc analysis from the 2-year CLARITY study demonstrated that Mavenclad reduced the risk of 6-month EDSS progression by 47% vs placebo - Patients with highly active multiple sclerosis had an even greater treatment effect, reducing the risk by 82% vs placebo Merck, a ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Japanese Ministry of Health, Labour and Welfare Grants SAKIGAKE designation for tepotinib, Merck's investigational highly selective c-Met receptor tyrosine kinase inhibitor - First regulatory designation for tepotinib - SAKIGAKE ...
Hamburg, Germany (ots/PRNewswire) - i Sasol Chemicals and HELM AG have entered into a long-term marketing agreement for ethylene glycols. The marketing agreement between Sasol and HELM comes into effect upon the start-up of Sasol's new ethylene oxide and ethylene glycol (EO/EG) units in Lake Charles, Louisiana, USA. Sasol's EO/EG unit has a nameplate capacity of 250.000 mt/year for monoethylene glycol (MEG) with ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in Argentina - Mavenclad has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years Merck, a leading science and technology company, today ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose ...
Hamburg, Germany (ots/PRNewswire) - Sasol Chemicals' Inorganics and Catalyst division announced the completion of its alumina capacity expansion at Sasol's Brunsbüttel site in Germany. The expansion will increase Sasol's alumina hydrate production capacity in Brunsbüttel by approximately 15,000 tons per annum, enabling the company to meet growing global demand for ...
Düsseldorf, Germany & Paris, France (ots) - ImmunoQure, a biotech company focused on the research and development of human autoantibodies as therapeutics for the treatment of common human diseases and the international pharmaceutical company Servier today announced the establishment of a Worldwide, exclusive ...
Nuremberg, Germany (ots/PRNewswire) - - Sydney knocks New York off 3rd place, while Melbourne jumps from 9th to 7th - Tokyo records greatest score gain of all 50 cities The latest Anholt-GfK City Brands IndexSM (CBISM) reveals that Paris retains its position at the top. For the fourth time since the survey began, the global public regards Paris as the highest rated out of 50 cities. Australian cities also show ...
Darmstadt, Germany and New York (ots/PRNewswire) - - Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer - Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage[1],[2] - Javelin Renal clinical development program is ongoing, including Phase III ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - First treatment in relapsing-remitting multiple sclerosis (RRMS) to show sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years - Updated registration follows recent approval of Mavenclad in Europe and Canada Merck, a leading science and ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. based media - Expanded Fertility Technology portfolio highlights Merck's commitment to improve fertility treatment outcomes for patients - U.S. commercial availability expected in first half of 2018 Merck, a leading science and technology company, today ...
Hamburg, Germany (ots/PRNewswire) - After concluding a successful token pre-sale round, FinTech company The NAGA Group is launching their main token sale, which begins today on December 1, 2017. JOIN HERE! (https://nagaico.com/?reason=prnewswire3) NAGA (https://nagaico.com/?reason=prnewswire3) is proud to have a ...
Münster, Germany (ots/PRNewswire) - COMPO EXPERT GmbH (COMPO EXPERT), a leading manufacturer of specialty fertilizers for commercial use has appointed Hans-Christian Nehlsen as its new Chief Financial Officer (CFO). As a proven financial controller with deep finance experience, Mr. Nehlsen will be responsible for the Finance and Accounting, Human Resources, IT and ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - Pivotal Phase III Javelin trial investigating avelumab as third-line treatment for patients with unresectable, recurrent or metastatic gastric cancer did not meet its pre-specified primary endpoint of superior overall survival ...
Markham, Ontario and Duren, Germany (ots/PRNewswire) - Acquisition Establishes Enghouse Networks Presence In Germany Enghouse Systems Limited (TSX: ENGH) announced today it has acquired XConnect GmbH, from XConnect Global Networks Ltd. Headquartered in Duren (outside of Cologne), XConnect GmbH provides carrier change processes and number portability services to telecommunication providers in Germany. Its software enables ...
Nuremberg, Germany (ots/PRNewswire) - When it comes to the factors that make up 'the good life', the top three most popular items selected by people internationally are good health, financial security and leisure time. These are followed by a happy marriage, travel for leisure, a home you own, and control over one's ...
Nuremberg, Germany (ots/PRNewswire) - - France leaps to second place for first time, while UK regains ground to remain third and Japan enters top five - USA is only country showing overall decline in 2017 - Germany major gains in Governance, People, and Culture In the wake of a substantial drop in global perception ...
Darmstadt, Germany (ots/PRNewswire) - - New pen is easy-to-learn and easy-to-use, supporting the one in six couples affected by infertility in the U.S.[1] - Insights of patients, nurses and doctors helped to evolve the product Merck, a leading science and technology company, today announced that the company received approval for a new version of GONAL-f® (follitropin alfa injection) prefilled pen from the U.S. Food and ...
Darmstadt, Germany (ots/PRNewswire) - - First multiple sclerosis (MS) therapy to achieve positive NICE recommendation in the shortest possible timeframe - Mavenclad has shown sustained clinical efficacy up to four years with a maximum of 20 days of oral treatment over two years Merck, a leading science and technology company, today announced that the National Institute ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K. based media. - Grant awarded across three research projects focused on prediction and defining characteristics of multiple sclerosis - Investment of EUR5 million in multiple sclerosis research funding as awards mark fifth year Merck, a leading science and ...
Darmstadt, Germany (ots/PRNewswire) - - Data suggests Mavenclad may significantly increase proportion of patients exhibiting no evidence of disease activity versus placebo - Analysis of 10,000 patient years of safety data provides further characterization of safety profile - Further data suggests the relative ...